Search results
Showing 46 to 52 of 52 results for bortezomib
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA573)
This guidance has been updated and replaced by NICE technology appraisal guidance 897.
Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.
This guidance has been updated and replaced by NICE technology appraisal guidance 427.
Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)
Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making
C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)
Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making
NICE leads the way in approving breakthrough treatment for multiple myeloma
People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.